REGENXBIO, Inc. (RGNX)
8.03
-0.44
(-5.19%)
USD |
NASDAQ |
Nov 12, 16:00
8.04
+0.01
(+0.12%)
After-Hours: 20:00
REGENXBIO Shareholders Equity (Quarterly) : 148.04M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 148.04M |
| June 30, 2026 | 71.76M |
| March 31, 2026 | 21.08M |
| December 31, 2025 | 102.73M |
| September 30, 2025 | 161.45M |
| June 30, 2025 | 213.68M |
| March 31, 2025 | 274.20M |
| December 31, 2024 | 259.65M |
| September 30, 2024 | 301.42M |
| June 30, 2024 | 348.27M |
| March 31, 2024 | 390.67M |
| December 31, 2023 | 311.74M |
| September 30, 2023 | 363.10M |
| June 30, 2023 | 405.86M |
| March 31, 2023 | 465.14M |
| December 31, 2022 | 516.20M |
| September 30, 2022 | 563.82M |
| June 30, 2022 | 630.52M |
| March 31, 2022 | 689.67M |
| December 31, 2021 | 764.30M |
| September 30, 2021 | 461.41M |
| June 30, 2021 | 507.24M |
| March 31, 2021 | 554.50M |
| December 31, 2020 | 377.75M |
| Date | Value |
|---|---|
| September 30, 2020 | 415.66M |
| June 30, 2020 | 397.86M |
| March 31, 2020 | 420.15M |
| December 31, 2019 | 450.20M |
| September 30, 2019 | 468.40M |
| June 30, 2019 | 494.59M |
| March 31, 2019 | 487.05M |
| December 31, 2018 | 508.85M |
| September 30, 2018 | 494.06M |
| June 30, 2018 | 317.22M |
| March 31, 2018 | 299.34M |
| December 31, 2017 | 183.03M |
| September 30, 2017 | 194.65M |
| June 30, 2017 | 211.70M |
| March 31, 2017 | 212.90M |
| December 31, 2016 | 161.74M |
| September 30, 2016 | 180.23M |
| June 30, 2016 | 196.18M |
| March 31, 2016 | 208.60M |
| December 31, 2015 | 216.81M |
| September 30, 2015 | 221.81M |
| June 30, 2015 | 82.63M |
| March 31, 2015 | 20.20M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| AbbVie, Inc. | -4.583B |
| Anika Therapeutics, Inc. | 137.58M |
| United Therapeutics Corp. | 6.276B |
| Biomea Fusion, Inc. | 7.586M |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 466.04M |
| Total Liabilities (Quarterly) | 318.00M |
| Debt to Equity Ratio | 1.704 |
| Current Ratio | 4.741 |
| Net Debt Paydown Yield | 0.78% |